Impact of the early reduction of cyclosporine on renal function in heart transplant patients: a French randomised controlled trial. - Archive ouverte HAL Access content directly
Journal Articles Trials Year : 2012

Impact of the early reduction of cyclosporine on renal function in heart transplant patients: a French randomised controlled trial.

(1) , (2) , (3, 4) , (5) , (6) , (7) , (8) , (9) , (10) , (11) , (12) , (13) , (1) , (14, 3) , (1, 15) , (2, 15)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
Ségolène Gaillard
  • Function : Author
  • PersonId : 934758
Annick Mouly-Bandini
  • Function : Author
  • PersonId : 934762
Agnès Sirinelli
  • Function : Author
  • PersonId : 934764
Eric Epailly
  • Function : Author
  • PersonId : 934765

Abstract

BACKGROUND: Using reduced doses of Cyclosporine A immediately after heart transplantation in clinical trials may suggest benefits for renal function by reducing serum creatinine levels without a significant change in clinical endpoints. However, these trials were not sufficiently powered to prove clinical outcomes. METHODS: In a prospective, multicentre, open-label, parallel-group controlled trial, 95 patients aged 18 to 65 years old, undergoing de novo heart transplantation were centrally randomised to receive either a low (130 < trough CsA concentrations <200 μg/L, n = 47) or a standard dose of Cyclosporine A (200 < trough CsA concentrations <300 μg/L, n = 48) for the three first post-transplant months along with mycophenolate mofetil and corticosteroids. Participants had a stable haemodynamic status, a serum creatinine level <250 μmol/L and the donors' cold ischemia time was under six hours; multiorgan transplants were excluded. The change in serum creatinine level over 12 months was used as the main criterion for renal function. Intention-to-treat analysis was performed on the 95 randomised patients and a mixed generalised linear model of covariance was applied. RESULTS: At 12 months, the mean (± SD) creatinine value was 120.7 μmol/L (± 35.8) in the low-dose group and 132.3 μmol/L (± 49.1) in the standard-dose group (P = 0.162). Post hoc analyses suggested that patients with higher creatinine levels at baseline benefited significantly from the lower Cyclosporine A target. The number of patients with at least one rejection episode was not significantly different but one patient in the low-dose group and six in the standard-dose group required dialysis. CONCLUSIONS: In patients with de novo cardiac transplantation, early Cyclosporine A dose reduction was not associated with renal benefit at 12 months. However, the strategy may benefit patients with high creatinine levels before transplantation. TRIAL REGISTRATION: ClinicalTrials.gov NCT00159159.
Fichier principal
Vignette du fichier
1745-6215-13-231.pdf (396.05 Ko) Télécharger le fichier
Vignette du fichier
1745-6215-13-231.xml (73.27 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Format : Other
Loading...

Dates and versions

inserm-00769687 , version 1 (03-01-2013)

Identifiers

Cite

Pascale Boissonnat, Ségolène Gaillard, Catherine Mercier, Michel Redonnet, Bernard Lelong, et al.. Impact of the early reduction of cyclosporine on renal function in heart transplant patients: a French randomised controlled trial.. Trials, 2012, 13 (1), pp.231. ⟨10.1186/1745-6215-13-231⟩. ⟨inserm-00769687⟩
445 View
326 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More